Stay updated on JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial

Sign up to get notified when there's something new on the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.2%
    Check dated 2024-06-13T22:01:00.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety profile and effectiveness monitoring of Empagliflozin in Korean patients with type 2 diabetes mellitus.
    Difference
    0.2%
    Check dated 2024-06-06T14:41:06.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that participants must be patients who have started on JARDIANCE® as per the approved label in Korea, be at least 19 years old, and have signed a data release consent form.
    Difference
    16%
    Check dated 2024-05-22T21:36:45.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    2%
    Check dated 2024-04-30T22:32:02.000Z thumbnail image

Stay in the know with updates to JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial

Enter your email address, and we'll notify you when there's something new on the JARDIANCE Post-Marketing Surveillance in Korean Type 2 Diabetes Clinical Trial page.